| Document |
Document Title |
|
WO/2013/073577 |
[Problem] To provide a compound which has a D-amino acid oxidase (DAAO) inhibitory effect and is useful, for example, as a prophylactic and/or therapeutic agent for schizophrenia and neuropathic pain. [Solution] The inventors have achiev...
|
|
WO/2013/071400 |
The present application relates to novel apocynin-lipoic acid covalent conjugates, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions that are mediated by oxidative...
|
|
WO/2013/071400 |
The present application relates to novel apocynin-lopioc acid covalent conjugates, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions that are mediated by oxidative...
|
|
WO/2013/072441 |
The present invention relates to a composition consisting of Vitamin C, L-glutamine, L-cystine or L-cysteine, riboflavin, succinic acid, fumaric acid, coenzyme Q10, and niacin. The present invention relates further to the use of the comp...
|
|
WO/2013/066398 |
In some embodiments, the present invention provides methods of treating oxidative stress in a subject by administering a therapeutic composition to the subject. In some embodiments, the therapeutic composition comprises a carbon nanomate...
|
|
WO/2013/063889 |
Provided is the use of multiflora glycoside in preparing an anti-hypoxic drug. A full body and cell level hypoxia model indicates that multiflora glycoside can significantly increase the survival time of a mouse with asphyxiant hypoxia, ...
|
|
WO/2013/061724 |
Provided are a novel radical inhibitor, a composition containing the same, and a radical generation inhibition method using the same. This radical inhibitor comprises a salen complex compound of a divalent metal.
|
|
WO/2013/059651 |
A compound having the formula (I) wherein X is S, SO or SO2; one of R1, R2, and R3 is O and the others of R1, R2 and R3 are independently, the same or different, CH2, or CR13 wherein, R13 is an alkyl group, an alkenyl group, an alkynyl g...
|
|
WO/2013/057675 |
The present invention relates to an alkenylglucosinolate composition which under stomach conditions generates the corresponding epithionitrile derivative, which has detoxifying properties. It also relates to a food composition containing...
|
|
WO/2013/055385 |
The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enha...
|
|
WO/2013/055385 |
The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enha...
|
|
WO/2013/051680 |
The purpose of the present invention is to provide an orally administered adsorbent comprising activated carbon fiber having high adsorption performance or removal performance, whereby a toxic substance inside the body can be adsorbed or...
|
|
WO/2013/051389 |
Provided are: a medicinal agent responsive to a metal salen complex compound, which can neutralize the cytotoxity of the metal salen complex compound and has a detoxifying activity; and a system for controlling the in vivo behavior of a ...
|
|
WO/2013/047082 |
The present invention addresses the problem of providing a means for efficiently degrading an exogenous opioid peptide. Provided is an exogenous opioid peptide-degrading enzyme comprising one or more components selected from the group co...
|
|
WO/2013/049519 |
The present invention relates to compositions, kits and methods for the administration of compositions and kits for supplementation with twelve carbon chain fatty acids or twelve carbon chain acylglycerols; and specifically for the suppl...
|
|
WO/2013/043085 |
The invention relates to various fields of medicine, pharmaceutics and pharmacology and the chemical pharmaceutical, pharmaceutical and parapharmaceutical industry, and specifically concerns a novel class of agents which exhibit modulato...
|
|
WO/2013/042065 |
The invention provides compounds which are inhibitor of ricin, abrin, Shiga or saporin and which have a bipartite configuration comprising an aromatic heterocyclic structure resembling an adenine moiety in size and shape connected at the...
|
|
WO/2013/042065 |
The invention provides compounds which are inhibitor of ricin, abrin, Shiga or saporin and which have a bipartite configuration comprising an aromatic heterocyclic structure resembling an adenine moiety in size and shape connected at the...
|
|
WO/2013/041090 |
The invention relates to the use of klinoptilolith or klinoptilolith-containing mixtures for producing medicinal products or other pharmaceutical products, for the absorption and removal of caesium ions from the human or animal organism....
|
|
WO/2013/043085 |
The invention relates to various fields of medicine, pharmaceutics and pharmacology and the chemical pharmaceutical, pharmaceutical and parapharmaceutical industry, and specifically concerns a novel class of agents which exhibit modulato...
|
|
WO/2013/042065 |
The invention provides compounds which are inhibitor of ricin, abrin, Shiga or saporin and which have a bipartite configuration comprising an aromatic heterocyclic structure resembling an adenine moiety in size and shape connected at the...
|
|
WO/2013/032893 |
The present invention provides compositions and methods for treating or protecting mucosal tissues from damage associated with radiation and/or chemotherapy. Specifically, the instant invention is directed to inhibitors of prolyl hydroxy...
|
|
WO/2013/029634 |
The invention relates to a composition from extract of Myrciaria dubia and Echinacea purpurea,which has a synergistic effect. The composition of the invention has potentiated antioxidant and anti-influenza properties, as well as a high i...
|
|
WO/2013/029034 |
The inventive tripartite composition is a combination of fucoidan, trans-resveratrol, and bovine colostrum in effective quantities, in the range of from 1 : 1.5: 1.5 to 1 : 10: 10 in weight percent. This composition provides antioxidant ...
|
|
WO/2013/026151 |
Stevia is a zero or low calorie natural sweetener that can be extracted from the leaves of Stevia Rebaudiana. An improved stevia rebaudiana extract is presently disclosed having low or no after-taste as well as a process for obtaining. T...
|
|
WO/2013/023443 |
The present invention aims at providing an application of a peptide of a soft-shell turtle in preparing a medicament having a protective feature against radiation hazards. The oligopeptide of the soft-shell turtle of the present inventio...
|
|
WO/2013/021093 |
The present invention relates to the use of cardiotrophin-1 (CT-1) for the prevention and/or treatment of acute renal injury, specially of acute kidney injury induced by nephrotoxic agents, such as contrast agents, antibiotics, immunosup...
|
|
WO/2013/022058 |
The purpose of the present invention is to establish a novel therapy method for hyperbilirubinemia and, therefore, to provide a bilirubin excretion enhancer. The present invention provides a bilirubin excretion enhancer comprising, as an...
|
|
WO/2013/017475 |
The present invention discloses the use of L-Histidine to reduce Gadolinium accumulation i nto target org ans, preventing its toxic effects, after administration of gadolinium based contrast agents. The invention thus, also disclose the ...
|
|
WO/2013/019145 |
The invention relates to the field of veterinary medicine and animal husbandry and, more specifically, to a method for producing a biologically active product of natural origin for use in veterinary science and animal husbandry, which ex...
|
|
WO/2013/016427 |
The invention concerns methods for protecting a subject in need from a deleterious effect of gluten ingestion. The invention specifically concerns the treatment of celiac disease and gluten intolerance. The invention further provides pha...
|
|
WO/2013/013497 |
Provided are a Hovenia Acerba drink effective at curing drunkenness, and the preparation method and use thereof in preparing anti-inebriation food and health care products. The drink is prepared from Hovenia Acerba, Flos Puerariae and Rh...
|
|
WO/2013/011732 |
[Problem] To provide a selective hydrogenation apparatus with which a hydrogen-containing biologically applicable liquid can be obtained without changing the properties of a biologically applicable liquid. [Solution] A hydrogen-generatin...
|
|
WO/2013/008076 |
The invention concerns a new polymorphic form of R-(+)-α-lipoic acid and a process for the preparation thereof, in addition to the compositions that contain it and its use as a medicine or food supplement.
|
|
WO/2013/008249 |
A cell regenerating antioxidant composition and the process for preparing the same made from commonly available flowers and fruits which includes banana flowers, cucumber fruits and chickpea to regenerate and repair the cells and tissues...
|
|
WO/2013/006055 |
The present invention relates to the fields of medical microbiology and vaccines. In particular the invention relates to a process for detergent-free preparation of outer membrane vesicles (OMV) of Gram negative bacteria for use in vacci...
|
|
WO/2013/006055 |
The present invention relates to the fields of medical microbiology and vaccines. In particular the invention relates to a process for detergent-free preparation of outer membrane vesicles (OMV) of Gram negative bacteria for use in vacci...
|
|
WO/2013/003445 |
The invention provides a novel tetra-pyridine compound and a composition containing this compound for protecting and preserving cells, tissues and organs against ischemia-reperfusion injury. A method and use of the tetra-pyridine compoun...
|
|
WO/2013/002317 |
A solid oxidized glutathione salt is produced by heating oxidized glutathione to at least 30°C while bringing the oxidized glutathione into contact with an aqueous medium composed of water and/or a water-soluble medium, in the presence ...
|
|
WO/2013/001890 |
[Problem] To provide a soy saponin composition having high bodily absorption characteristics. [Solution] This soyasapogenol composition contains soyasapogenol B and 3-O-D-glucuronopyranosyl soyasapogenol B. The weight ratio (B/A) of the ...
|
|
WO/2012/167656 |
The invention provides spriulina polysaccharide organic bio-active iodine and application thereof. The spriulina polysaccharide organic bio-active iodine is obtained by adding spriulina polysaccharides and organic bio-active iodine into ...
|
|
WO/2012/167346 |
The present invention relates to anti-ricin antibodies and uses thereof. More specifically, the invention relates to anti-ricin antibodies and fragments thereof as well as their use in therapy or prophylaxis.
|
|
WO/2012/167236 |
Provided are stable liquid and solid formulations of oxidized and reduced mitochondria-targeted antioxidants, and methods of their preparation and use.
|
|
WO/2012/163290 |
The present invention discloses a pharmaceutical polymer and a method for quenching free radicals. Said pharmaceutical polymer comprises a glycopeptides and an aminothiol moiety which covalently bonds together. The disclosed pharmaceutic...
|
|
WO/2012/159569 |
Provided in the present invention is an application for PRDX2 and/or PRDX6 in the preparation of a pharmaceutical composition to treat or prevent damage, aging or disease resulting from an increase in reactive oxygen species (ROS).
|
|
WO/2012/155061 |
A method of inhibiting, preventing, or reducing damage to non-cancerous cells in a human subject during chemotherapeutic treatment or radiation treatment of cancer cells in the human subject includes administering to the human subject ar...
|
|
WO/2012/150370 |
The present invention relates to a combination of the polyphenols resveratrol, quercetin and catechin in a molar ratio of approximately 1:1:2 or, alternatively, approximately 1:1:5, which has synergic antioxidant power. This combination ...
|
|
WO/2012/147901 |
The present invention provides a composition for mitigating anticancer drug side effects, the composition containing isoleucine, leucine and valine as active ingredients. The composition is extremely safe and moreover will not impact the...
|
|
WO/2012/146057 |
Disclosed is a curcuminoid injection solution mainly composed of curcuminoid, a solvent used for injection and a small amount of pH adjusting agent. Also provided is a curcuminoid intravenous injection which simply mixes the aforemention...
|
|
WO/2012/145307 |
In an embodiment, a barrier-forming composition includes a carbohydrate gum, a humectant, and an antimicrobial agent. The composition furthermore meets the following requirements: about 0.01% ≤ C ≤ about 0.4%; about 4.5% ≤ H ≤ ab...
|
